Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02918630 · ClinicalTrials.gov registry record · NA

E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia

A NA study of Tobacco Smoking, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
NA
Development phase
7
Enrollment target
1
Study location

NCT02918630 is a NA study of Tobacco Smoking that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 7 participants, below the 477-participant average among 38 other Tobacco Smoking trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02918630, a NA study of Tobacco Smoking, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
NA
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess if access to an electronic nicotine delivery device, or e-cigarette, in addition to nicotine patch (21 mg) can help reduce cigarette smoking among individuals diagnosed with schizophrenia compared to nicotine patch alone.

Conditions Studied

Interventions

  • DRUG Nicotine Patch
  • DRUG E-cigarette

Study Locations (1)

Texas

  • University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2016-10
Est. Completion 2017-08
Phase NA

What the Registry Record Tells You About NCT02918630

The ClinicalTrials.gov registry entry for NCT02918630 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 477-participant average among 38 other Tobacco Smoking trials with a reported enrollment target (99% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Smoking appearing as the primary indexed condition, and to 2 interventions - of which Nicotine Patch is the first listed.

NCT02918630 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02918630 about?

NCT02918630 is a clinical study titled "E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia". The purpose of this study is to assess if access to an electronic nicotine delivery device, or e-cigarette, in addition to nicotine patch (21 mg) can help reduce cigarette smoking among individuals diagnosed with schizophrenia compared to nicotine patch alone.

What is the current status of trial NCT02918630?

This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2016-10. Estimated completion is 2017-08.

What conditions does trial NCT02918630 study?

This clinical trial studies the following conditions: Tobacco Smoking.

What interventions are being tested in trial NCT02918630?

The interventions under investigation include: Nicotine Patch (DRUG), E-cigarette (DRUG).

Who is sponsoring clinical trial NCT02918630?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02918630 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.